A closer look at Rion’s exosome hair serum trial, its placebo comparison, author disclosures and the questions raised by Retraction Watch.
On October 21, 2026, Retraction Watch raised questions about the evidence and author disclosures behind a trial of Rion’s exosome hair serum. The report described Rion as a Mayo Clinic spinoff. It examined how the researchers interpreted their results and an undisclosed relationship between an author and the company.
The trial had been published the previous March in PRS Global Open. For readers assessing exosome hair products, the central issue is the comparison behind the claim: did participants receiving the serum improve more than those receiving placebo?
According to Retraction Watch, the paper said the serum improved hair density and volume fullness as well as hair and scalp health. Those are the benefits presented by the researchers. The report also described results that make their interpretation less straightforward.
The placebo group had slightly higher average increases in follicle count, hair strength and hair quality. Yet statistically significant increases were reported only among participants receiving the exosomes.
These statements describe different aspects of the findings. An average change describes what happened to a measured outcome within a group. Statistical significance addresses how that change was evaluated through an analysis. Neither phrase should be read in isolation from the comparison the study was intended to make.
This report concerns a particular formulation and trial. It is not a biological explanation of how exosomes affect hair follicles, and product publicity is not a substitute for that evidence.
Retraction Watch reported that the trial included 39 participants. Only eight were assigned to placebo, creating an approximately 80:20 treatment-to-placebo allocation.
The distinction between improvement within a group and improvement compared with another group is central here. A treatment group can show a statistically significant change from its own starting point without demonstrating that its change was greater than the placebo group’s change.
Retraction Watch explained that a much larger treatment group can make statistical significance more likely even when the groups experience similar changes over time. That helps explain why the statistical label and the direction of the average results need to be considered together.
The slightly higher placebo averages do not, by themselves, establish that placebo was superior. Equally, statistical significance among serum recipients does not establish that the serum outperformed placebo. The relevant evidence is the analysis comparing the groups.
For someone considering a commercial product, that distinction matters more than whether a promotional summary uses the word “significant.” A statistical label is not a promise of an everyday result. The useful question is whether the comparison supports a reasonable expectation of benefit beyond the control condition.
Biostatistician Frank Harrell Jr. of Vanderbilt University Medical Center criticized the allocation and analyses in comments to Retraction Watch. He described the design as far from a 1:1 ratio and considered the analyses misleading.
Coauthor Rod Rohrich disputed that characterization. He said the allocation was intentional so that more participants would receive the active formulation during an initial efficacy and safety evaluation. He also agreed that a larger, more evenly powered trial would help confirm and extend the findings.
Rohrich described the trial as double-blind and placebo-controlled, with a duration of nine months. Those features are relevant to its design. They do not independently answer the specific criticism about group allocation and analysis.
The disclosure issue is separate. According to Retraction Watch, Rohrich coauthored the trial with Rion founder Atta Behfar and other researchers. Behfar and several authors disclosed relationships with Rion, but Rohrich’s relationship was absent from the paper’s disclosure statement.
Retraction Watch reported that Rohrich had served as a Rion consultant. Rohrich called the omission an oversight and said he would correct it. That account supports scrutiny of the disclosure, not a conclusion that the omission was deliberate.
The report also addressed the journal connection. Rohrich founded PRS Global Open in 2013 and became its editor emeritus in December 2020. The journal said he had not been involved in editorial operations since his term ended. His former leadership role is context, not evidence that the hair trial’s publication process was compromised.
A separate retraction discussed in the report needs its own boundary. A 2025 study involved Exo-HL and four adults with chronic leg wounds. It was retracted after the authors learned that the product came from cultured plant cells rather than the human stem cells described in the paper.
That wound study involved a different product and condition. Its retraction is not evidence for or against the hair serum’s efficacy. Its relevance is the importance of establishing product identity before interpreting a study’s conclusions.
Finally, this assessment draws on Retraction Watch’s reporting rather than an independent reanalysis of participant-level trial data. It explains the reported disagreement without supplying a new effect estimate or substituting a fresh analysis for the original results.
The practical response is to ask more precise questions, rather than treating either a positive headline or a critical report as the whole answer. For this trial, the most useful questions follow directly from the issues Retraction Watch documented:
These are questions for evaluating evidence, not instructions for selecting or using a treatment. Readers can bring them to a qualified clinician when a personal hair-loss decision is involved. A discussion grounded in the actual comparison is more useful than one based solely on the word “exosome.”
For broader context, Younell’s review of uncertainty around exosome treatments provides a companion perspective. Readers considering a treatment discussion can also consult our overview of prescription approaches to female hair loss.
The next useful development would be evidence that addresses the disputed comparison directly. Rohrich’s acknowledgment that a larger, more evenly powered trial would help confirm the findings provides a clear research direction.
For now, the central question remains whether this serum produces better hair outcomes than placebo in a comparison designed and analyzed to establish that difference. The October report makes that question more visible. A convincing answer will depend on the results and their analysis, not on the novelty of the product category.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
